News Coverage 08.05.19 By: John Carroll Share on Twitter Share on Facebook Share on LinkedIn Close to a decade after Eli Lilly killed it, Jeffrey Bluestone’s ‘breakthrough’ drug is back and being steered to the FDA Related Announcement, Press Release Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer Announcement, Press Release Parker Institute for Cancer Immunotherapy Collaborates with Conquer Cancer and ASCO to Support Promising Cancer Research Announcement Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer
Announcement, Press Release Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer
Announcement, Press Release Parker Institute for Cancer Immunotherapy Collaborates with Conquer Cancer and ASCO to Support Promising Cancer Research
Announcement Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer